Jazz Pharmaceuticals PLC (JAZZ) is Asymmetry Capital Management L.P.’s 4th Largest Position

Asymmetry Capital Management L.P. reduced its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,339 shares of the specialty pharmaceutical company’s stock after selling 2,352 shares during the period. Jazz Pharmaceuticals PLC comprises about 5.8% of Asymmetry Capital Management L.P.’s portfolio, making the stock its 4th biggest holding. Asymmetry Capital Management L.P. owned about 0.05% of Jazz Pharmaceuticals PLC worth $4,873,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Parametric Portfolio Associates LLC lifted its stake in shares of Jazz Pharmaceuticals PLC by 23.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,466 shares of the specialty pharmaceutical company’s stock valued at $4,131,000 after purchasing an additional 5,427 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Jazz Pharmaceuticals PLC by 1,074.9% in the 1st quarter. Victory Capital Management Inc. now owns 3,278 shares of the specialty pharmaceutical company’s stock valued at $476,000 after purchasing an additional 2,999 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Jazz Pharmaceuticals PLC by 19.4% in the 1st quarter. Alliancebernstein L.P. now owns 4,211 shares of the specialty pharmaceutical company’s stock valued at $611,000 after purchasing an additional 684 shares during the period. Finally, BB&T Securities LLC acquired a new position in shares of Jazz Pharmaceuticals PLC in the 1st quarter valued at $279,000. Hedge funds and other institutional investors own 88.34% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.23% during midday trading on Thursday, hitting $142.24. 176,261 shares of the stock were exchanged. The stock has a market cap of $8.54 billion, a P/E ratio of 21.91 and a beta of 1.05. The firm has a 50-day moving average price of $148.70 and a 200-day moving average price of $151.57. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same period in the previous year, the firm posted $2.67 EPS. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

Several equities analysts recently issued reports on JAZZ shares. HC Wainwright started coverage on shares of Jazz Pharmaceuticals PLC in a research note on Friday, August 25th. They issued a “neutral” rating and a $144.00 target price for the company. Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, June 27th. Morgan Stanley started coverage on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price for the company. Wells Fargo & Company reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. Finally, J P Morgan Chase & Co reiterated a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $179.79.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/10/12/jazz-pharmaceuticals-plc-jazz-is-asymmetry-capital-management-l-p-s-4th-largest-position.html.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul L. Berns sold 662 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now directly owns 6,599 shares of the company’s stock, valued at approximately $939,499.63. The disclosure for this sale can be found here. Insiders sold a total of 9,297 shares of company stock valued at $1,429,417 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply